Watson Pharmaceuticals is seeking federal approval to make a generic version of Alcon Inc.'s eye treatment, the company said Friday, just one day after Alcon filed a patent lawsuit against Watson.
Vigamox treats an eye inflammation called bacterial conjunctivitis. Watson said the antibiotic solution generated $281 million in U.S. sales for the 12 months that ended Feb. 28.
Watson Pharmaceuticals Inc., headquartered in Corona, Calif., filed an abbreviated new drug application with the Food and Drug Administration. Alcon filed a lawsuit in U.S. District Court to prevent Watson from making and selling the product before its U.S. patents expire. It seeks a stay of final FDA approval for the Watson patent until Sept. 1, 2013.